On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...

In exchange, Arrowhead will receive an upfront payment of $500 million and an equity investment of $325 million in its common stock. The company will also receive $250 million in annual installments ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.